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Breast cancer is currently the most frequent, fatal
cancer of women in western countries. While
estrogens have a widely understood involvement in
breast cancer, a significant but not yet fully
understood role for androgens has also been
suggested. The principal androgen, testosterone, is the
obligate steroidal precursor of estradiol, but
can equally be metabolized into dihydrotestosterone,
a more potent, pure androgen. Both androgens exert
their distinctive biological effects via the androgen
receptor, which is coexpressed with estrogen receptor
alpha in 80 to 90% of breast cancers. The hormonal
control of breast development and pathology has
been examined experimentally through the use of
animal models, notably mice and rats. This review
summarizes the data from experimental rodent
models on the effects of androgens in experimental
breast cancer, aiming to address the importance of
androgens and the androgen receptor in the origins
and pathogenesis of breast cancers, as well as to
discuss potential biomarker and therapeutic
opportunities arising from novel insights based on the
experimental research.produced mainly in the testes, but to a lesser extent inIntroduction
Breast cancer is currently among the most frequent and
fatal cancers afflicting women worldwide. The strongest
epidemiological clues to the hormonal origins of breast
cancer arise from the recognition of lifetime endogenous
estrogen exposure comprising early menarche, incessant
ovulation, and late first lactation and menopause. While
estrogens have a widely understood involvement, we [1]
and others (reviewed in [2]) have demonstrated a signifi-
cant but not yet fully understood role for androgens in
breast cancer. The hormonal control of breast* Correspondence: djh@anzac.edu.au
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stated.development and pathology has been examined through
animal model experimentation, most frequently involv-
ing mice and rats.
This review summarizes the experimental data using
rodent models on the effects of androgens in experimental
breast cancer, aiming to highlight the role of androgens
and androgen receptor (AR)-mediated androgen effects in
experimental breast cancers. In addition, the review aims
to lay a solid foundation for a consensus, as well as guid-
ance for future research into novel biomarkers and thera-
peutic targets arising from novel insights acquired from
experimental research. Owing to increased interest in an-
drogen actions in breast cancer, we will cover the histor-
ical aspects briefly, but concentrate on the most recent
literature focusing on the role of androgens in experimen-
tal rodent breast tumorigenesis. This focus on experimen-
tal animal models aims to provide a complementary view
to recent reviews of androgens and breast cancer, which
concentrate on clinical data and human breast cancer cell
lines [2,3].Androgens, androgen receptor and breast cancer
Androgens and the androgen receptor
Androgens are a group of 19-carbon steroid hormones
other steroidogenic tissues such as ovaries, adrenal glands,
and placenta, as well as in peripheral tissues, including
adipose tissue and mammary glands. Dehydroepiandros-
terone (DHEA) and androstenedione are pro-androgens
(androgen precursors) capable of being converted into tes-
tosterone and/or dihydrotestosterone (DHT) in peripheral
and androgen target tissues. The major circulating andro-
gen, testosterone, either can be aromatized (via aromatase
enzyme) into estradiol (E2) acting via estrogen receptor
(ER) signaling or can be reduced (via 5α-reductases) within
target tissues to the nonaromatizable androgen DHT,
which has higher androgenic bioactivity than testosterone
and is associated with a higher affinity for AR [4], leading
to more potent androgen signaling. While DHT is ad. The licensee has exclusive rights to distribute this article, in any medium, for
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versibly to 3β-androstanediol that may activate ERβ [5].
Androgens (testosterone, DHT) and pro-androgens
(DHEA, androstenedione) are the most abundant sex
hormones produced in women, with the normal ovary
producing larger amounts of androgens than E2; however,
E2 is two orders of magnitude more potent on a molar
basis than testosterone or DHT. Testosterone serves as an
obligate precursor for E2 synthesis, so androgens play
an indirect but necessary role in female physiology.
Yet ARs are also expressed in virtually every tissue
in women, including breast tissue, suggesting a direct
physiological role for the AR-mediated androgen ef-
fects [6].
Evidence for the role of androgens in human breast cancer
Significant roles for androgens in human breast cancer
susceptibility and as treatment options have received
more attention recently. The AR is expressed in 70 to
90% of breast cancers, comparable with ERα (70 to 80%)
and progesterone receptor (50 to 70%) positivity. Yet AR-
negative breast cancers respond poorly to hormone
therapy with reduced overall survival, while conversely
AR-positive cancers are smaller with fewer lymph node
metastases corresponding to a better prognosis, thus dem-
onstrating the role of the AR as a biomarker [7]. Im-
portantly, AR expression is detected in about 10 to 50% of
triple-negative (ER, progesterone receptor and Her-2)
breast cancers that respond poorly to traditional therapies
(reviewed in [3]). Similarly, natural models of high en-
dogenous androgen exposure – such as women suffering
from polycystic ovarian syndrome and congenital adrenal
hyperplasia, as well as men with much lower risk of
breast cancer when compared with women – support
the concept that androgen action may protect against
breast cancer [8,9].
Rodent breast cancer models
The history of experimental breast cancer has been
reviewed extensively [10], and therefore our aim is to
concisely describe the models used to explore the role of
androgens in experimental rodent breast cancers.
Chemical carcinogenesis
One of the most remarkable findings in breast cancer
research is the ability to induce breast-specific tumors in
rodents, usually not susceptible to spontaneous breast can-
cer, using chemical carcinogens [11]. Common molecular
mechanisms that possibly underlie chemical carcinogenesis
involve activating mutations of ras proto-oncogenes [12].
Interestingly, the activation of ras proto-oncogenes follow-
ing chemical carcinogenesis could be regulated by other
signaling pathways. This hypothesis was demonstrated by a
lack of H-ras-activating mutations and upregulation at theexpression level following 7,12-dimethylbenz(a)anthracene
(DMBA)-induced skin carcinogenesis in PTEN knock-
out mice [13]. Similarly, androgens acting via AR could
regulate ras proto-oncogene activation in chemical carcino-
genesis as supported in hormonally induced prostate cancer
[14]. Androgens could therefore modify carcinogen-
induced mammary tumors either by directly regulating pro-
liferation and cell cycle via targeting growth factors or by
the regulation of underlying molecular mechanisms in
chemical carcinogenesis.
Dimethylbenz(a)anthracene and methylcholanthrene
Most early research examining the role of androgens
in carcinogen-induced experimental breast cancer used
methylcholanthrene (MCA) [15,16]. But DMBA has be-
come the current mainstay because only a single dose is
required to induce mammary tumors in 100% of female
rats with a mean time of 95 days (reviewed in [17]). DMBA
and MCA are polycyclic aromatic hydrocarbons that act
through the aryl hydrocarbon receptor. They are also pro-
carcinogens requiring cytochrome P450 (1A1, 1A2 and
1B1) activation to become carcinogens and subsequently
form metabolite-DNA adducts. Aryl hydrocarbon re-
ceptor activation transcriptionally regulates cytochrome
P450 (CYP) enzymes, but can also act directly by regulat-
ing cell growth, apoptosis, and transition to an invasive,
metastatic phenotype [18]. Aryl hydrocarbon receptor ac-
tivation and inducible CYP systems are therefore central
to chemical carcinogenesis induced by polycyclic aromatic
hydrocarbons, a process that may be susceptible to regula-
tion by androgens [19,20]. DMBA treatment also induces
ovarian damage characterized by small afollicular ovaries
and reduced circulating androgens [1,21], but with in-
creased circulating follicle-stimulating hormone and
luteinizing hormone [1]. This damage is more prominent
in mice than rats, which may contribute to mice hav-
ing a greater susceptibility to DMBA-induced mammary
tumors.
N-Nitroso-N-methylurea
In contrast to DMBA and MCA, N-nitroso-N-methylurea
is a direct-acting carcinogen that does not require meta-
bolic activation. This carcinogen can be advantageous in
experiments that involve co-treatments or genetic modifi-
cation, which may influence CYP activation [16].
Hormonal carcinogenesis
Spontaneous breast cancer is very rare in rodents and
therefore hormonal treatments are required to induce
breast cancers (early work extensively reviewed in [22]).
Long-term continuous exposure to exogenous E2 or the
pro-estrogen estrone (E1) in rats induces a high inci-
dence of mammary tumors that frequently metastasize.
Tumor latency depends on the estrogen dose as well as
Table 1 Promoters driving transgene expression in
mammary cells
Promoter Origin Expression
MMTV-LTR Mouse mammary tumor virus Breast epithelial cells,
several other tissues
WAP Whey acidic protein Secretory mammary
epithelium
C3(1) Rat prostate steroid-binding
protein
Epithelial cells of prostate
and mammary gland
B-LG Bovine β-lactoglobulin Mammary gland
MT Metallothionein Most mammary cells
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for estrogen-induced carcinogenicity include activation
of ER signaling pathways [23] or the metabolism of
estrogen into oxidative metabolites having genotoxic,
mutagenic, transforming, and carcinogenic effects [24]. An-
drogen actions could therefore either modify ER-dependent
signaling [25] or the metabolism of E2 and E1 by P450 en-
zymes [26]. Administration of either natural (progesterone)
or synthetic (medroxyprogesterone acetate) progestins
increases the carcinogen-induced mammary tumor inci-
dence in mice [27]. Medroxyprogesterone acetate may
function as a promoter for DMBA-induced carcinogen-
esis or by increasing the incidence of DMBA-induced
mutations involving the H-ras proto-oncogene [27]. How-
ever, it is important to note that medroxyprogesterone
acetate is also a potent activator of AR [28].Spontaneous carcinogenesis
Some specific rodent strains are highly prone to spontan-
eous mammary tumor formation. Spontaneous mammary
tumors occur over a range from 40% for Fischer rats to
over 80% for Buff/N rats [29]. Similarly the C3H mouse
strain with a high lifetime incidence (>70%) of mammary
tumors has been used to study androgen effects on
mammary tumors [30]. Mammary tumors in C3H mice
are mainly due to the presence of mouse mammary tumor
viruses that induce tumors by acting as insertional muta-
gens, which in turn activates the expression of cellular
proto-oncogenes. Viral transcription is regulated by spe-
cific sequences within the long terminal repeat that are
also responsive to androgen action [31] and could modify
the initiation of tumors, but cannot explain the androgen
effect on existing tumors. Rat and mouse lines differing in
their sensitivity to spontaneous mammary tumors have
been used to determine genetic components, including
dominant resistance genes as well as sensitivity genes
that modify susceptibility to spontaneous and/or in-
duced mammary tumors and could be shared by human
tumors.Genetically modified mouse models
The development of genetically modified, transgenic
or knockout, mouse models has greatly advanced our
understanding of the molecular basis of initiation, promo-
tion, and progression of breast cancer. Numerous genetic
mouse models used in breast cancer studies include APC,
BRCA1, ERBB2 (Neu), p53, and PTEN knockout mouse
models (reviewed in [10]). Mammary gland-specific, tar-
geted inactivation of relevant genes such as the Ar (Cre-
loxP using promoters targeting mammary cells; Table 1)
combined with breast cancer models are promising ap-
proaches to investigate androgenic regulation of specific
pathways and effects on mammary gland pathology [32].Relevance of rodent breast cancer models to human
breast cancer
Rodent models are irreplaceable for exploring the in vivo
biology and mechanisms of tumor initiation, promotion,
progression, and metastasis. These models provide unique
help to identify otherwise unrecognized opportunities for
novel treatment and diagnostic or prognostic markers
through experiments not feasible in humans. Mammary
tumors in rodents and humans display many etiological
similarities. In both species, spontaneous tumors develop
late in life and with low frequency, while genetic factors
increase both the susceptibility and frequency of but re-
duce the latency of overt tumors ([33]; see Androgens and
spontaneous rodent carcinogenesis). Furthermore, hormo-
nal induction of breast cancer is directly proven in rodent
models and is a well-accepted inference in human breast
cancers from large observational studies of estrogen-
treated women [34]. Similarly, carcinogen-induced experi-
mental breast cancer is proven in rodents (for example,
polycyclic aromatic hydrocarbons) and is suspected (see
Androgens and chemical carcinogenesis) but less clearly
established in human breast cancers. While no single ro-
dent model can address all aspects of human breast can-
cer, different experimental models provide complementary
findings to decipher the heterogeneity of established but
fragmentary pathophysiological knowledge currently
available. The evaluation of experimental breast cancer
model(s), while quite germane to human breast cancer,
must therefore consider critically the appropriate ca-
veats on the design and interpretation of findings for
such species extrapolation.
Different experimental breast cancer models have dis-
tinct features that should be considered in choosing an
optimal model for the study of interest. Considerations
should include histological similarities as well as the
degree of genetic or transcriptomic similarity (including
steroid hormone receptor expression and hormone sensi-
tivity). Although it is desirable to use similar morphological
descriptors to describe human and rodent mammary tu-
mors, the morphology of rodent tumors is quite distinctive
and trained pathologists would not confuse them with
human tumors [35]. For example, the main histotypes in
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adenocarcinomas or squamous cell carcinomas [1], while
the latter are very rare in women [36]. On the other hand,
spontaneous tumors tend to have hyperproliferation of
both connective and glandular tissues and are generally
classified as fibroadenomas [37].
Interestingly, while mammary tumor development in
rodents and women is highly estrogen dependent [38],
rat mammary tumors are mainly estrogen responsive
whereas mouse mammary tumors are mainly estrogen
independent, with human breast cancers falling between
rat and mouse tumors with regard to estrogen sensitivity
[38]. To integrate the estrogen-independent mammary
tumors in mice into a more estrogen-sensitive frame-
work, specific ER-positive mammary tumor mouse
models have been developed (references cited in [39])
and we found that DMBA generates both ERα-positive
and ERα-negative tumors in mice [1]. These ER-positive
models could therefore be used to test the possible
modifying effect of androgens on ERα-dependent effects
in breast cancer [25].
The transcriptomic similarity of human breast cancers
and experimental mammary tumors in mouse models
has been analyzed recently [39]. Where some models
developed tumors with model-specific gene expression
and histopathological patterns (for example, TgC3(1)-Tag
model) suitable for specific mechanistic studies, others
had greater diversity of tumors (for example, DMBA) [39].
Like human breast cancers, mouse mammary tumors can
also be divided into basal or luminal types of clusters –
although luminal tumors with estrogen responsiveness
and ERα positivity are less common in mice compared
with women [39].
Rodent breast cancer models have the advantage of
being able to produce a wide variety of breast cancer
subtypes that are observed in breast cancer patients.
Hence, using a judicious choice of rodent models allows
researchers to investigate different subtypes of breast
cancer by creating specific opportunities as a platform to
study underlying biological mechanisms of mammary
carcinogenesis, which cannot be directly investigated in
humans. With the appropriate design of experiments as
well as careful selection of experimental models, rodent
models allow the identification of basic processes in
breast cancer development, but also the means to test
the roles of specific pathways as well as potential prevent-
ive and curative agents.
Effects of androgens in rodent breast cancer models
Androgens and chemical carcinogenesis
Chemical carcinogens, notably DMBA, MCA, and N-
nitroso-N-methylurea, have been widely used in experi-
mental studies to explore the role of androgens in breast
cancer since the mid twentieth century (Tables 2, 3 and 4).The chemical carcinogen studies are categorized into
androgen effects on tumor incidence (Tables 2 and 3)
or regression (Table 4) as discussed below.
Androgen effects on tumor incidence
Studies have shown (Tables 2 and 3) that androgen treat-
ment of rodents before the appearance of palpable DMBA,
MCA, or N-nitroso-N-methylurea-induced tumors signi-
ficantly decreased mammary tumor incidence [15,40-46]
and increased latency [40,46].
Androgens (testosterone propionate (TP), unesterified
testosterone, DHT) or pro-androgens (DHEA) were gen-
erally administered by subcutaneous injection around the
time of chemical carcinogen treatment, with the duration
of androgen treatment varying from single injection to
continuous treatment until tumor(s) developed. As noted
previously (see Androgens and the androgen receptor),
some androgens can be enzymatically modified to other
potent bioactive steroids such as the aromatization of
testosterone into E2 and the 5α-reduction to DHT, while
other androgens may be metabolized to corresponding
estrogens or activated or inactivated by 5α-reduction. Si-
milarly, DHT can be reduced to 3-diols [47], while the
pro-androgen DHEA can be metabolized to testosterone,
DHT or E2. Nevertheless, despite different androgens be-
ing used in these experiments, all of the studies reported
that androgens reduced chemically induced mammary
tumor incidence (Table 2) and increased tumor latency at
certain doses of androgen treatment. These findings imply
that the strong, AR-mediated androgen effect on tumor
incidence in carcinogen-induced mammary tumors could
be via AR-dependent regulation of cell proliferation and/
or CYP-mediated carcinogen activation and formation of
DNA adducts as discussed in Chemical carcinogenesis.
The mechanism(s) for androgen-induced inhibition of
chemically induced mammary carcinoma still remains
unclear. Androgens may inhibit pituitary and ovarian
function [48]; however, androgens could also have direct
effects because rodent mammary epithelium as well as
carcinogen-induced mammary tumors are AR-positive
[49,50]. This latter interpretation of direct effects is sup-
ported by the fact that potent DHT inhibition of the
growth of DMBA-induced mammary tumors persists in
ovariectomized rats [51].
DMBA-induced tumor incidence has also been examined
after neonatal androgenization of female rats (Table 3)
[52-57], with androgens first injected between 0 to 5 days
after birth and treatment varying from a single injec-
tion to continuous treatment until the end of the ex-
periment. Most studies [52-55], but not all [56,57], found
that, like peri-pubertal treatments, neonatal androgeni-
zation reduced tumor incidence. The protective role of
neonatal androgenization could be due to depressed pitu-
itary and ovarian function following neonatal androgen
Table 2 Androgen effects on tumor incidence (induced by chemical carcinogens)
Reference Animal model Type of androgen Dosea Duration Incidence
7,12-Dimethylbenz(a)anthracene
Briziarelli [40] SD ratsb TP 0.01, 0.05, 0.5, 1 or 1.5 mg daily 30 days ↓ (at doses of 0.5 to 1.5 mg)c
Briziarelli [41] SD rats TP 0.13, 0.26, 0.4 or 10.5 mg daily 10 days ↓ (0.26 only)
Li and colleagues [42] SD rats DHEA (Not described) Implant ↓
Luo and colleagues [43] SD rats DHEA 5, 10 or 20 mg daily 9 months ↓




Shay and colleagues [15] Wistar rats T 37 or 75 mg Implant ↓
Shay and colleagues [45] Wistar rats T 75 mg Implant ↓
N-Nitroso-N-methylurea
Lubet and colleagues [46] SD rats DHEA 5, 24, 120, 600 or 2,000 mg/kg
DHEA in diet
109 days ↓ (600/2,000)
DHEA, dehydroepiandrosterone; SD, Sprague–Dawley; T, testosterone; TE, testosterone enanthate; TP, testosterone propionate. aSome doses are shown as weekly
doses calculated based on the dosing regime in the original article. bFemale rats unless otherwise specified. cWhen TP treatment started 10 or 20 days
after 7,12-dimethylbenz(a)anthracene but not later.
Choi et al. Breast Cancer Research 2014, 16:483 Page 5 of 12
http://breast-cancer-research.com/content/16/6/483treatment [53,54] or reduced P4 levels in sexually mature
females that could modify the response to carcinogens
[55]. This hypothesis is supported by the finding that P4
treatment of neonatally androgenized females increased
the DMBA-induced mammary cancer incidence [58]. In
addition, neonatal androgenization causes lactational dif-
ferentiation of the mammary epithelium [52,59] that may
modify responses to DMBA.
DMBA alone does not induce mammary tumors in
Sprague–Dawley male rats, whereas when E2 is co-
administered 50% develop tumors within 26 weeks [38].
This is comparable with our findings in male mice where
DMBA caused enlargement of mammary lymph nodes,
but not the growth of mammary tumors in either wild-
type or AR knockout males for up to 39 weeks [1]. These
findings demonstrate that exposure to ovarian hormones,
notably the sole bioactive estrogen E2, is necessary to pro-
mote carcinogen-induced rodent mammary tumors.
Androgen effects on tumor growth
Most studies [51,60-79], but not all [16], found that andro-
gen treatment after the appearance of palpable, chemicallyTable 3 Neonatal androgen effects on tumor incidence (induc
Reference Animal model Type of andro
7,12-Dimethylbenz(a)anthracene
Kovács [52] Wistar ratsa TP
Shellabarger and Soo [53] SD rats TP
Christakos and colleagues [54] SD rats TP
Yoshida and colleagues [55] SD rats TP
Purnell [56] LEW/Mai rats TP
Verhoeven and colleagues [57] Female and male SD rats TP
SD, Sprague–Dawley; TP, testosterone propionate. aFemale rats unless otherwise spinduced mammary tumors caused tumor regression
(Table 4).
Administration of the nonaromatizable androgen dros-
tanolone (2,10,13-trimethyl DHT) propionate (40 mg/kg,
5/week for 6 weeks) to rats had no effect on DMBA-
induced or MCA-induced mammary tumors [16]. Yet both
DMBA-induced and MCA-induced mammary tumors
regressed following ovariectomy, demonstrating that the
tumors remained hormone dependent. One explanation
could be the dose dependency of androgen effects, as low
dose (12 or 6 mg/kg weekly) induced tumor regression,
consistent with another study using a different DHTanalog
(2α-methyl DHT) [49], whereas a very high TP dose
(210 mg/kg weekly) stimulated DMBA-induced tumor
growth [61]. These dose dependencies may reflect direct
cross-reactivity of very high DHT doses with off-target
estrogen or other receptor mechanisms.
Effect of anti-androgens or androgen receptor inactivation
on mammary tumors
The anti-androgen flutamide has been used to investigate
the role of androgens in chemical carcinogen-induceded by chemical carcinogens)
gen Dose (mg) Duration Incidence
2.5 Single injection ↓
1.25 Single injection ↓
1.25 Single injection ↓
1.25 Daily until the end of the experiment ↓
1.25 Single injection No effect
0.5 Single injection No effect
ecified.
Table 4 Androgen effects on tumor growth (induced by chemical carcinogens)
Reference Animal model Type of androgen Dosea Tumor growth
7,12-Dimethylbenz(a)anthracene (using androgens)
Young and colleagues [60] SD ratsb T 1.2 to 6 mg weekly ↓
DHT 1.2 to 6 mg weekly
Heise and Gorlich [61] SD rats TP 6 to 180 mg/kg weekly ↓ (low dose only)
Teller and colleagues [62] SD rats MDTP and TP Total of 480 mg for 8 weeks ↓
Shimkin and colleagues [16] SD/Wistar rats DP 200 mg weekly for 6 weeks No effect
Teller and colleagues [63] SD rats MDTP and TP 3.75 to 60 mg weekly for 8 weeks ↓
Teller and colleagues [64] SD rats MDTP 60 mg weekly for 8 weeks ↓
Mobbs [67] SD rats TP 10 or 50 mg/kg weekly or a single 60 mg pellet ↓ (high dose only)
Griswold and Green [68] SD rats MDTP and TP 10 mg/kg daily for 20 days ↓
Briziarelli and colleagues [69] SD rats FBTA 2 or 4 mg daily for 30 days ↓
Takahashi and colleagues [70] SD rats MDTP and TP 6 mg weekly ↓
Quadri and colleagues [71] SD rats DmP 0.5 mg daily for 3 weeks ↓
Horn and colleagues [72] Inbred rats Calsterone 10 mg daily for 2 to 3 weeks ↓
Costlow and colleagues [73] SD rats TP 8 mg weekly ↓
Zava and McGuire [74] SD rats TP 2.4 mg weekly ↓
Teller and colleagues [65] SD rats MDTP 200 mg/kg weekly for 5 weeks ↓
Teller and colleagues [66] SD rats MDTP 3 to 100 mg/kg weekly for 4 weeks ↓ (dose dependent)
Dauvois and colleagues [51] SD rats DHT 3 cm silastic implant (30/100, DHT/cholesterol, w/w) ↓
Boccuzzi and colleagues [75] SD rats DHEA 4 mg daily for 21 days ↓
Boccuzzi and colleagues [76] SD rats DHT 25 μg DHT daily for 20 days ↓
Gatto and colleagues [77] SD rats DHEA 4 mg daily for 20 days ↓
Methylcholanthrene (using androgens)
Ercoli and Briziarelli [79] SD rats DHT or DHT enol ethers 2 mg daily for 30 days ↓
Shimkin and colleagues [16] SD/Wistar rats DP 200 mg/kg weekly for 6 weeks No effect
7,12-Dimethylbenz(a)anthracene (using anti-androgens)
Spinola and colleagues [78] SD rats Flutamide 10 mg daily for 20 days ↓
Boccuzzi and colleagues [76] SD rats Flutamide 2 mg daily for 20 days ↓
DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; DmP, dromostanolone propionate; DP, drostanolone propionate; FBTA, 9α-fluoro-11β-hydroxybenzo[d,e]
testosterone 17-acetate; MDTP, 2α-methyl-DHT propionate; SD, Sprague–Dawley; T, testosterone; TP, testosterone propionate. aSome doses are shown as weekly doses
calculated based on the dosing regime in the original article. bFemale rats unless otherwise specified.
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edly inhibited the growth of DMBA-induced mammary
tumors in female rats, contrasting with the inhibitory
effect of androgens. The most probable mechanism is
that flutamide has weak direct partial agonist effects
on AR when sufficiently high flutamide doses are applied
on a low androgenic background (for example, in female
or castrated animals) [80]. Other less likely mechanisms
include: inhibition of adrenal steroid production, which is
implausible given the rodent adrenal’s negligible androgen
output [81]; or reduced endogenous P4 secretion [78], due
to neuroendocrine effects on pituitary and/or ovarian
hormone secretion [82]. The uncertainties reflect the
limitations of using solely pharmacological probes to de-
fine steroidal molecular mechanisms.Using an androgen receptor knockout (ARKO) andro-
gen-insensitive female mouse model (expressing a mutated,
inactive AR) combined with DMBA chemical carcino-
genesis, however, we demonstrated that the onset of palp-
able mammary tumors was significantly faster in ARKO
females compared with wild-type female mice (median
time, 22 weeks vs 34 weeks, respectively) [1], supporting
the inhibitory role of AR-mediated androgen actions in
mammary carcinogenesis. This observation predicts that
otherwise healthy women who are heterozygous for the
functional and inactive AR alleles (for example, mothers
of children with androgen insensitivity) could also be at
increased risk of breast cancer, although this prediction
remains to be tested. This prediction is also supported
by increased breast cancer susceptibility in women with
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repeats [83]. The relationship between AR CAG repeats
and breast cancer susceptibility could be further tested
using a humanized mouse model where AR activity is
modified [84] by replacing the rodent Ar gene with most
of the human Ar exon 1 CAG repeat length variant [85].
Hence, investigating the relationship between AR CAG re-
peats and breast cancer susceptibility may provide direct
insight into the relationship between AR activity and breast
cancer susceptibility in humans. This relationship has been
suspected [83,86] but not experimentally explored.
Effect of aromatase inhibitors on mammary tumor growth
Aromatase inhibitors inhibit mammary tumor growth in
rodents [78,87,88]. Aromatase inhibitors cause increases
in circulating testosterone concentrations with decreased
E2 concentrations in both rodents [78,88] and women
[89]. Although the protective role of aromatase inhibi-
tors on breast cancer due to reduced E2 concentrations
is well established, the role of the concomitant increases
in serum testosterone concentration has usually been
overlooked, and could be further explored using genetic-
ally modified models with altered aromatase expression
[90-93]. However, not only may aromatase inhibitors in-
crease circulating endogenous androgen concentrations,
but some possess intrinsic androgenic activity by binding to
and activating the AR [78,87] – highlighting the limitations
of pharmacological blockade of steroidal mechanisms,
where blockers or their metabolites may have off-
target effects. The protective role of aromatase inhibi-
tors in breast cancer could therefore also be due to direct
androgenic effects. This is supported by the superior
efficacy of the aromatase inhibitor letrozole over the
ER blocker tamoxifen (lacking AR activation) [94]. Hence,
the effectiveness of aromatase inhibitors as breast cancer
treatment may involve their largely overlooked direct
androgenic effects on tumors, an interpretation that war-
rants further evaluation.
Androgens and hormonal carcinogenesis
Proof of the experimental induction of mammary cancer
by the pro-estrogen E1 as well as E2 in the 1940s was a
landmark in the investigation of hormone-dependent
breast cancer [95]. In rats, co-administration of testoster-
one increased latency for the appearance of E1-induced
palpable tumors, in a dose-dependent manner [96]. In
addition, administration of testosterone to rats already
bearing E1-induced mammary tumors decreased the tumor
area [96,97]. These findings further support a protective
role of androgens in experimental carcinogenesis, despite
the mechanism of tumor induction (carcinogen or hor-
monally induced). This implies either direct AR-mediated
regulation of cell proliferation or perhaps similar mecha-
nisms involving induction of experimental tumors.In contrast, Noble demonstrated that simultaneous
treatment with E1 and TP in Noble rats significantly in-
creased the incidence of mammary tumors compared
with E1 treatment alone [98], further supported by more
recent studies [99-101], although high doses of testoster-
one also reduced the latency of E2-induced tumors
[101]. Testosterone may act as an endogenous promoter
in estrogen-induced mammary carcinogenesis via stimula-
tion of paracrine secretion of growth factors in mammary
glands or oncogenes in mammary cells, rather than through
the stimulation of breast cell proliferation [101]. However,
the reasons for the contradictory findings on the impact of
testosterone on hormone-induced breast cancer remain
unknown.
Androgens and spontaneous rodent carcinogenesis
Specific rat and mouse lines that develop spontaneous
mammary tumors have been used to investigate the role
of androgens in the incidence of these tumors, as well as
their growth as tumor transplants (Table 5). Growth of
80% of spontaneous mammary tumors was prevented by
TP treatment [102], while testosterone or DHT treatment
induced significant regression of transplanted tumors
[103]. DHT administration to ovariectomized rats caused
greater regression of tumor growth, suggesting a direct
effect on tumor cells; however, a contributory effect of
androgens in reducing ovarian hormone secretion due to
negative hypothalamic feedback mechanisms could not be
excluded [103].
Most studies [30,102,104-108], but not all [109,110],
demonstrated that the treatment of mice with TP or the
pro-androgen DHEA before the development of palpable
tumors reduced the incidence of tumors in mice (mainly
C3H). In contrast, postnatal treatment (days 1 to 5) of
SHN or BALB/cfC3H female mice with DHT or testos-
terone significantly increased mammary tumor incidence
when compared with vehicle-treated control groups
[109,110]. These opposite effects could be related to
timing of the androgen exposure, but the significance
is still uncertain.
Androgens and genetically modified mouse breast cancer
models
In our studies, androgen-insensitive female mice (global
ARKO model) have increased susceptibility to DMBA-
induced mammary tumors, which demonstrates direct
mammary gland-specific effects of androgens acting via
the AR [1]. A study using Cre/LoxP-mediated conditional
deletion of the Ar allele in mammary epithelium demon-
strated that reduced epithelial AR expression also pro-
moted the early onset of Neu (ERBB2) proto-oncogene
tumors [32], suggesting that the AR in mammary epithelial
cells may have a significant role in AR-dependent protec-
tion against experimental breast cancer. Yet transgenic rats
Table 5 Androgen effects on spontaneous tumor growth/incidence
Reference Mouse/rat Carcinogen Dosea Duration Tumor growth/
incidence
Tumor growth (treatment after palpable tumors)
Heiman [102] White ratb Spontaneous/
autotransplant
5 to 15 mg TP (total dose) 4 to 6 months ↓
Huggins and Mainzer [103] SD rat Transplants 6 mg T/DHT weekly 7 weeks ↓
Nathanson and Andervont [30] C3H mice Spontaneous 7 to 17.5 mg TP weekly 4 weeks No effect
Tumor incidence (treatment before palpable tumors)
Jones [104] C3H mice Spontaneous 1.5 mg TP weekly (weeks 1 to 3);
1 mg TP weekly (weeks 4 to 45)
45 weeks ↓
Nathanson and Andervont [30] C3H mice Spontaneous 1.5 mg TP weekly At 4.5 months of age
for 4 months
↓
Lacassagne and Raynaud [105] C3H mice Spontaneous 4 mg TP weekly Beginning a few days
after birth
↓
Loeser [106] Strong A
strain mice
Spontaneous 28 to 56 mg TP (total dose) Implant ↓
Schwartz [107] C3H mice Spontaneous 1,350 mg/kg DHEA weekly 5 to 29 weeks of age ↓
Heiman [108] RIII mice Spontaneous 8 to 9 mg TP (total dose) 6 to 7 months of age for 8
to 16 months
↓
Yanai and colleagues [109] SHN mice Spontaneous 1 mg DHT daily (prenatal) or
0.2 mg DHT daily (neonatal)
GD 12 to 15 (prenatal) or daily
for 5 days after birth (neonatal)
↑ (neonatal)
Mori and colleagues [110] BALB/cfC3H
mice
Spontaneous 0.02 or 0.005 mg T daily Days 1 to 5 after birth ↑
DHEA, dehydroepiandrosterone; DHT, dihydrotestosterone; GD, gestation day; SD, Sprague–Dawley; T, testosterone; TP, testosterone propionate. aSome doses are
shown as weekly doses calculated based on the dosing regime in the original article. bFemale rats/mice unless otherwise specified.
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oped mammary tumors only in males and not in females,
suggesting that the development of tumors was androgen
dependent [111]. This androgen dependency was further
supported by findings that orchidectomy prevented male
mammary tumor development while DHT treatment
restored it. This discrepancy between mouse and rat
models targeting the ERBB2 pathway may be due to the
fact that the mouse model overexpressed the mutated
form of ERBB2 [32], whereas the rat model overexpressed
nonmutated ERBB2 [111] and rat tumors were strongly
AR-positive while mouse tumors had low AR immuno-
positivity. While only few studies have so far utilized the
ARKO mouse models, in the future these models (both
global and cell-specific ARKO) combined with various
transgenic experimental breast cancer models may be
uniquely enlightening when exploring the cell-specific role
of AR as well as the influence of AR-mediated androgen
actions on specific carcinogenic pathways.
Discussion and conclusions
Rodent models have been used to investigate hormonal
mechanisms in experimental breast cancer, but the lack
of uniformity of findings – in terms of experimental
design, species, strain, mechanism of tumor induction,
and types of androgens used – renders it difficult to de-
velop an integrated explanatory mechanism. Yet, despiteconsiderable variability in study design, most rodent stud-
ies suggest a protective role for androgens at several stages
of experimental breast cancer. Nevertheless, a minority
suggests that androgens increase, or anti-androgens pro-
tect against, experimental breast cancer. The reasons for
these discrepancies may provide potentially important
clues to unravel the role of androgens in experimental
breast cancer. The suggested explanatory framework in-
volves a biphasic effect of androgens with low or moderate
doses inducing tumor regression, while higher doses have
no or stimulatory effects on tumor growth. The growth-
promoting effect at high androgen doses could be via
ER-dependent mechanisms: either via enzymatic conver-
sion of aromatizable androgens used or via direct binding
of supraphysiological androgen concentrations to the ER.
AR-mediated androgen signaling has recently been sug-
gested to be inhibitory in ERα-positive breast cancers,
opposing the effect of estrogens, while androgens in the
presence of AR may activate the oncogenic properties of
AR in ERα-negative tumors (reviewed in [2]). This con-
cept is also utilized in the clinical setting, where AR
inhibition is considered a potential therapeutic target for
ERα-negative but not AR-positive breast cancers. The
influence of androgens on experimentally induced ERα-
positive or ERα-negative cancers has not been systematic-
ally evaluated in rodent studies. This is possibly due to the
difficulty in developing estrogen-dependent, ERα-positive
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the development of ERα-positive tumors in rats [74]
and mice [1], and thus could allow for the comparison
of tumor progression between ERα-positive and ERα-
negative tumors. Similarly, while ERα status is usually
analyzed in experimental breast cancer models, AR ex-
pression has not been systematically determined. Much
more in-depth analysis of AR expression and the role of
AR-mediated androgen action as well as modifying factors
is therefore necessary to optimize the opportunity affor-
ded by the role of androgen action at all stages of experi-
mental breast cancer.
These opportunities are being developed with therap-
ies targeted to AR or androgen production involved in
recently initiated, empirically motivated clinical trials
[112-114]. Interestingly, the anti-androgen bicaluta-
mide showed some treatment efficacy in a phase II clinical
trial testing treatment for ER-negative/AR-positive breast
cancers (ClinicalTrials.gov NCT00468715) [112]. How-
ever, as discussed above regarding anti-androgens in
experimental breast cancer, anti-androgens such as
bicalutamide can also have agonist properties, demon-
strated clinically by a decline in serum prostate-specific
antigen following bicalutamide withdrawal [115]. Largely,
the mechanisms of androgen actions as well as the modi-
fying factors involved are still not sufficiently well known.
More detailed mechanistically oriented experimental work
on androgen metabolism, on the mechanisms of androgen
action, as well as on modifying/interacting factors for the
role of the AR in breast cancer is therefore still needed in
order to develop efficient and better targeted androgen
therapies.
In conclusion, while androgens are assumed inhibitory
and estrogens stimulatory for mammary cell proliferation
in experimental settings, it is possible that the ratios of
these hormones and/or their respective receptors may
regulate the optimal balance in tissue maintenance and if
disturbed will lead to pathological/malignant growth. As
the AR is one of the most abundant steroid receptors
present in breast cancers, more research is warranted to
understand androgen actions via the AR in breast tissue
as a regulator for optimal hormonal balance and to pro-
vide opportunities for novel therapeutic targets and prog-
nostic biomarkers for this lethal disease.
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